15 22 22 26 30 2018 36 40 42 44 46 Focus 14 2018

16 2017 17 17 18 19 19 20 20 20 10 2018 15

16-20 Open Up the Future 2020 5,000 1,000 2020 2015 2017 2020 2015 11 30 4,257 4,338 5,000 2016 4 2021 3 5 1,069 785 1,000 593 579 700 646 790 800 25.9% 26.0% 40% 2017 2017 3.8%791 2016 16-20 Open Up the Future 2 2017 2.3% 4,338 16.9%785 17.9%772 18.7% 579 1.5% 3,093 70.0% 385 2017 8 2017 123 2017 741,544 38350 2017 10 75 16 2018

1 10 4,000 20174 5 2020 4,000 10 2017 4 MT-5547 MT-6548 MT-5199 MT-2271 2016 5 MT-2355 Hib5 2017 10 ND0612 2018 2 STNM01 2 2016 647 2017 790 2018 845 22 2 3,000 2020 75% 2018 4 2020 2020 3,000 1 2015 55%2020 75% 201737% 2017 5 2018 6 3 DPP-4 SGLT2 2017 9 DPP-4 SGLT2 2018 17

BIKEN 2017 9 2017 1.9%1,894 63% 2018 4 20203,000 2017 11 1. 26 2018 8 3,000 2 201820172.5315 1 8002 3 MT-2271 VLP Virus Like ParticleMT-2271 2018 2019 VLP ND0612 3 800 2020 2,000 1,200 MT-2271 ND0612 800 2 3 2020 800 2,000 20171 MCI-186 2017 5ALS 8 2017 122018 4 2018 5ASEAN 2 2. ALS 36 18 2018

ESG 2015 SDGs Sustainable Development Goals 4 200 2020 2015 5,000 2015 9 6,176 2020 2015200 5,000 2017 30 30 2015140 2017100 2018190 20175,158 2 RPA Robotic Process Automation 40 42 MCHC KAITEKI MOS Management Of Sustainability Sustainability Health Comfort 3 MOS Health Health QOL SDGs KAITEKI MOS WEB MCHC http://www.mitsubishichem-hd.co.jp/kaiteki_management/kaiteki/ http://www.mitsubishichem-hd.co.jp/sustainability/mos/ 2018 19

14 3 56 66 63.9% 40.9% 2018 2011 3 3 2018 2020 2018 2018 56 66.8 1 2017 56 2018 5 9 2018 56 1 10 63.9% 66.8% 10 2017 110 10 ESG 49 62 10 10 2017 10 11466 2017 10 IFRS50% 2017 2017 10 1 10 110 3 2018 4 20 2018

10 2018 2018 5 9 2017 2018 4,338 4,350 +0.3% 785 700 10.9% 579 470 18.9% 2018 9 2018 21

4 POC 2017 2017 POC 1 MT-8554 MT-7117 POC MT-4129 MT-0814 MT-2990 2 1. 2. 22 2018

20172018 2017 2018 MT-1303 S1P MT-5547 NGF 2/3 2/3 MT-7117 1 2 POC MT-2990 ) 1 2 POC MT-6548 HIF-PH 3 3 2020 TA-7284 SGLT2 MT-3995 CREDENCE * * NASH 2 2019 6 CREDENCE MT-5199 VMAT2 2/3 2/3 2021 MT-8554 2 2 3POC ND0612 2017 10 3 MT-1186 ALS 1 MT-2355 5 3 3 MT-2271 VLP 3 2018 2019 2018 23

POC 2018 3 2017 3 JOINUS in vitro 4 Stepping Up to the Future 2 2017 U.S.A. 24 2018

3 3 WEB URL CSR https://www.mt-pharma.co.jp/shared/show.php?url=../ csr/report/consumer_issues/index.html 3. 4. 2018 2018 2018 25

2017 2017 4 MT-5199 MT-5547 MT-6548 3 ALS 2018 2018 MT-5199 MT-5547 MT-6548 5 MT-2355 MT-7117 MT-8554 POC MP-513 3 26 2018

MR 2017 MT-2412 2 MCI-186 ALS 2018 6 TA-7284 2 MP-214 MP-214 2018 6 MCI-186 ALS MCI-186 ALS 2018 4 5 FTY720 FTY720 2018 5 TA-7284 2 CANVAS / CANVAS-R MT-210 3 MT-4580 3 2018 27

2017 3,000 75 AMP AMP 2017 5 3 2017 37% 2017 3 2017 10 DPP-4 SGLT2 2 2017 9 3 2017 No.1 BIKEN 2017 9 2017 11 PAF * * Platelet Activating Factor 28 28 2018

2018 2017 AMP MR WEB URL CSR AMP 2018 https://www.mt-pharma.co.jp/shared/show.php?url=../ csr/report/consumer_issues/information.html https://www.mt-pharma.co.jp/shared/show.php?url=../ csr/report/consumer_issues/reliability.html Stepping Up to the Future MR MR 2010 MR * 2018 4 MR MR MR MR MR * MR 2018 29

2018 2018 5 9 4,000 3,000 2,000 1,000 0 3,239 3,080 3,142 14 15 16 3,093 2018 17 2,962 18 2018 14 15 16 17 18 706 694 668 646 555 104 129 249 321 350 62 141 165 175 170 159 168 189 169 73 79 95 112 127 131 11 5 34 56 76 32 41 49 47 49 18 32 4 68 73 137 127 99 112 75 95 99 87 91 71 63 54 52 55 V 35 36 39 52 43 39 49 59 50 55 2016IFRS 2015 IFRS2014 30 2018

TNF TNF 1 646 8 20022003 2009 2012 4 2017 2002 5 20173.2%646 2018 42018 3 2018 2017 14.1%555 TNF TNF 4 1 321 2017 201729.0%321 4 1 3 2018 4 2011 9 2018 20182017 9.2%350 2018 31

2018 DPP-4 1 1 3 175 2 2013 20175.8%175 DPP-4 2015 2 2018 2017 2.8%170 2012 9 H1 169 2007 OD2015 7 15 201710.7%169 2018 3 6 7 152018 2017 56.6%73 2000 10 32 32 2018

SSRI 2002 100 SSRI 127 2011 2015 SAD 201713.2%127 SSRI 2 2018 2017 3.1%131 2011 8 SGLT T-1095 80 56 SGLT2SGLT2 2013 SGLT2 201760.8%56 SGLT2 2 2014 9 SGLT2 SGLT2 20182017 36.5%76 2018 33

2018 1 47 1 1 80 2011 11 20173.5% 47 2017 2 No.1 2 20182017 5.4%49 BIKEN 2017 5 350 BIKEN BIKEN BIKENBIKEN 2017 10.0% 3502017 2017 50 2018 2017 4.2% 365 34 2018

2017 DPP-4SGLT2 2 2 DPP-4 SGLT2 2 1 1 1 201718 2017 9 2018 2 2017 9 2018 2017 79.6%32 PAF 2001 80PAF PAF 2017 11 20174 2017 11 PAF DUAL 201868 2018 35

4 2020800 2021 3 1 2 2,000 3 2 1 2017 8 PatientPhysician Payer 3P 3 1 2,000 2 MT-2271 ND0612 2017 8 ALS 36 2018

2017 8 ALS 2018 83,000 2017 123 ALS 3P 2017 12 2018 4 5 ASEAN 2018 315 ALS ND0612 MT-2271 1 2 3 2021 MTHA 2 2017 10 1,24011 ND0612 2017 VLP MT-2271 3 2018 2020 800 2017 IT MTHA 2 1 2 3 38 39 2018 37

VLP VLP VLP Virus-Like Particle 1997 2013 VLP VLP VLP 5 6 VLP 5 62009 VLP VLP VLP MESSAGE VLP MT-2271 VLP VLP VLP VLP VLP CEO D 38 2018

ND0612 ND0612 2003 ND0612 40 50 100 140 10 1 ND0612 24 MESSAGE CEO S 2018 39

2018 4 CMC CMC 2 1 CMC CMC 1. 40 2018

2017 8 CMC 2007 5 2 2 1 1 2 2. WEB URL CSR 2018 2018 ND0612 MT-2271 https://www.mt-pharma.co.jp/shared/show.php?url =../csr/report/consumer_issues/manufacturing.html MT-8554 MT-7117 MT-2990 2 2018 41

2017 2022 ASEAN 3 8% 21 2018 4 2018 210 G1/G2 10 * 80%G180% G2 G1 6 G2 101.5 2019 12,000 % 12 12 % 100 2020 80% 9,000 9 8 75 6,000 6 4 50 3,000 3 0 25 35.8% 0 13 14 15 16 17 Copyright 2018 IQVIA. IQVIA World Review Analyst 2018 2013 1 2017 12 0-4 0 13 14 15 16 17 09 11 13 15 17 19 Copyright 2018 IQVIA. IQVIA 2013 4 2018 3 42 2018

* 4 2020 201580 120 200 2017100 140 2018190 2021 2015 5,000 2015 6,089 2017 5,158 931 250 200 150 100 50 0 16 80 140 190 200 65 15 95 45 120 80 17 18 20 2018 43

16-20 OJT 1 Off-JT 2 2017 1. On the Job Training 2. Off the Job Training & LGBT 2017 LGBT LGBT LGBT ALLY MBO Management by Objective OJT Off-JT 4 OJT www28www: Win-Win Woman e LGBT 2* % 2017 MT-VIVID 2 OJT OJTO 20 15 10 5 2 15.1% 7.8% 0 16 17 18 4 1 * 44 2018

MCHC 2006 5 MCHC 2017 10 EHS 2011 2017 URL WEB CSR MCHC KAITEKI KAITEKIMCHC WEB http://www.mitsubishichem-hd.co.jp/kaiteki_management/kaiteki/ 2016 4 https://www.mt-pharma.co.jp/shared/show.php?url=../csr/report/labor_practices/index.html https://www.mt-pharma.co.jp/shared/show.php?url=../csr/report/human_rights/index.html MTPC 2018 45

Focus 2010 2010 2017 Employee Assistance Program * QOL 2017 i 2 Healthcare * i 2 HC i 2 HC MCHC PDCA i 2 HC 3 EAP 46 2018

i 2 HCMCHC i 2 HC 2017 75% 10 1,000 ALS i 2 HC 500 2 2018 541 500 2013 2016 MTPC 2017 3 1 2 2019 1 86% 6 9 5,000 ICT 9 20182 1 PDCA 2018 47